Covira Surgical engages in the development of drugs that modulate the biological activity of the gut microbiome's resident bacteria. It is based on the work of Dr. John Alverdy, MD, a world authority on the molecular basis of post-surgical infections. Covira’s platform technology generated a lead asset (CS-0003) that modulates bacterialvirulence and restores microbial communities to prevent post-surgical infection. Covira’s approach is transformative to the field and the world is taking notice...in the 4th quarter of last year, Business Worldwide Magazine named Covira Among the 2021 - Top 20 Most Innovative Companies to Watch.

Biotechnology

Covira

Org chart

Teams

Similar companies